Home › Multiple Myeloma
Pag-aaral pangklinika para sa Multiple Myeloma na nagre-recruit sa U.S.
239 pag-aaral para sa Multiple Myeloma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- New York City, NY59 pag-aaral
- Boston, MA45 pag-aaral
- Atlanta, GA42 pag-aaral
- Houston, TX39 pag-aaral
- Durham, NC36 pag-aaral
- Nashville, TN31 pag-aaral
- Denver, CO26 pag-aaral
- St. Louis, MO26 pag-aaral
- Rochester, MN25 pag-aaral
- Columbus, OH25 pag-aaral
- Chicago, IL24 pag-aaral
- Milwaukee, WI23 pag-aaral
- Baldwin Park, CA23 pag-aaral
- Seattle, WA22 pag-aaral
- Miami, FL22 pag-aaral
- Salt Lake City, UT22 pag-aaral
- Edison, NJ21 pag-aaral
- Washington, DC21 pag-aaral
- Charlotte, NC21 pag-aaral
- Queens, NY19 pag-aaral
- Detroit, MI19 pag-aaral
- Jacksonville, FL19 pag-aaral
- Dallas, TX18 pag-aaral
- San Francisco, CA17 pag-aaral
- Omaha, NE17 pag-aaral
- Birmingham, AL17 pag-aaral
- Cincinnati, OH17 pag-aaral
- Winston-Salem, NC16 pag-aaral
- Cedar Rapids, IA16 pag-aaral
- Phoenix, AZ16 pag-aaral
- Philadelphia, PA16 pag-aaral
- Tampa, FL15 pag-aaral
- Los Angeles, CA15 pag-aaral
- Clifton, NJ15 pag-aaral
- Portland, OR14 pag-aaral
- New Rochelle, NY14 pag-aaral
- Cleveland, OH14 pag-aaral
- Irvine, CA14 pag-aaral
- Staten Island, NY13 pag-aaral
- Greenburgh, NY13 pag-aaral
Ayos sa estado
- Alabama22 pag-aaral
- Arizona28 pag-aaral
- Arkansas9 pag-aaral
- California68 pag-aaral
- Colorado36 pag-aaral
- Connecticut17 pag-aaral
- Delaware3 pag-aaral
- District of Columbia10 pag-aaral
- Florida54 pag-aaral
- Georgia49 pag-aaral
- Idaho3 pag-aaral
- Illinois33 pag-aaral
- Indiana18 pag-aaral
- Iowa19 pag-aaral
- Kansas12 pag-aaral
- Kentucky15 pag-aaral
- Louisiana10 pag-aaral
- Maine4 pag-aaral
- Maryland23 pag-aaral
- Massachusetts47 pag-aaral
- Michigan27 pag-aaral
- Minnesota31 pag-aaral
- Missouri27 pag-aaral
- Montana5 pag-aaral
- Nebraska19 pag-aaral
- Nevada3 pag-aaral
- New Hampshire4 pag-aaral
- New Jersey37 pag-aaral
- New Mexico5 pag-aaral
- New York74 pag-aaral
- North Carolina53 pag-aaral
- North Dakota5 pag-aaral
- Ohio46 pag-aaral
- Oregon21 pag-aaral
- Pennsylvania23 pag-aaral
- Rhode Island6 pag-aaral
- South Carolina8 pag-aaral
- South Dakota3 pag-aaral
- Tennessee31 pag-aaral
- Texas53 pag-aaral
- Utah22 pag-aaral
- Virginia20 pag-aaral
- Washington30 pag-aaral
- West Virginia3 pag-aaral
- Wisconsin30 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
18F-Fluciclovine PET/CT in Multiple Myeloma
Nagre-recruitPhase 2
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT06103838MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT06152575Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT02682667Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Nagre-recruitPhase 3
Edad 18 hanggang 79 · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07285239Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 10, 2026 · NCT07555938A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 10, 2026 · NCT05650632Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT05312255Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT06993675At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT05969860A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT05137054cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT05366881FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
Nagre-recruitPhase 1
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07221032BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07009899Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT06948084A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07393282A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT07589634A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT05201781A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Nagre-recruitPhase 2
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT07149857A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT05552222A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT05652335A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT07258511A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT04634552Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
Nagre-recruitObservasyonal na pag-aaral
Edad 10 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT06323447A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT07099391Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT07341867Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.